Peptide Library

Human study PLS-00198

In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.primary · Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2013-12-17 · PMID 24650966 · DOI

Design and participants

Design
Cross-sectional study
Population
Human branch-duct intraductal pancreatic mucinous neoplasm (IPMN) tissue samples with low or high grade dysplasia: surgical specimens, tissue microarrays and EUS-FNA samples.
Conditions
Intraductal pancreatic mucinous neoplasm, Pancreatic neoplasm
Setting
Laboratory analysis of surgical and endoscopic ultrasound fine-needle aspiration specimens.
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research support, non-U.S. government (per publication type); funder not named.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors concluded that ubiquitin and thymosin-β4 are overexpressed in IPMN with high grade dysplasia, and that positive staining on EUS-FNA material supports preventive resection.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • inappropriate population: The study examines endogenous thymosin-β4 expression in pancreatic tumour tissue. Nobody received thymosin-β4, so it says nothing about treatment effects.
    • abstract only: Only the abstract is available in the record. Sample details, methods and funding specifics cannot be checked.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 24650966, abstract (Conclusion, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 24650966, abstract (Experimental design, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 24650966, title (publication types metadata) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 24650966, abstract (Results, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).